INTERVIEW: The bigger value picture behind Cardinal Health's Cordis buy

When Johnson & Johnson agreed to sell Cordis to Cardinal Health for nearly $2bn last month, many saw Cardinal Health taking on a portfolio of mature medical devices – albeit of a well-established and globally recognized brand – that did not offer that much differentiation from the competition. So what’s in it for Cardinal Health and what’s the overriding objective behind the move? Tina Tan speaks to Don Casey, CEO of Cardinal Health’s Medical Segment, who spent nearly 26 years at J&J, to find out more about the underlying market changes and the strategy that motivated the company to make not only this particular acquisition, but likely more similar deals in the future